1,2-双[(2S,5S)-2,5-二乙基膦烷基]苯(1,5-环辛二烯)三氟甲磺酸铑(I)

• 产品号: 698407
• CAS号: 142184-30-3
• 分子式: C31H48F3O3P2RhS
• 分子量: 722.6242516

产品别名

• 标题: 1,2-Bis[(2S,5S)-2,5-diethylphospholano]benzene(1,5-cyclooctadiene)rhodium(I) trifluoromethanesulfonate
• IUPAC标准名: λ^1-rhodium(1+) ion (2S,5S)-1-{2-[(2S,5S)-2,5-diethylphospholan-1-yl]phenyl}-2,5-diethylphospholane cycloocta-1,5-diene trifluoromethanesulfonate
• IUPAC传统名: λ^1-rhodium(1+) ion (2S,5S)-1-{2-[(2S,5S)-2,5-diethylphospholan-1-yl]phenyl}-2,5-diethylphospholane 1,5-cyclooctadiene triflate
• 别名: (S,S)-Et-DUPHOS-Rh

产品登记号

• CAS号: 142184-30-3
• MDL号: MFCD00269861

产品性质

• Empirical Formula (Hill Notation): C31H48F3O3P2RhS
• GHS警示词: Warning
• GHS危险声明: H315-H319-H335
• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• GHS警示性声明: P261-P305 + P351 + P338
• 危险公开号: 36/37/38
• 安全公开号: 26
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Packaging
50, 250 mg in glass bottle
Legal Information
Sold in collaboration with Kanata Chemical Technologies Inc. for research purposes only. These compounds were made and sold under license from E.I. du Pont de Nemours and Company, which license does not include the right to use the compounds in producing products for sale in the pharmaceutical field.
Application
DuPhos and BPE Ligands: Highly Efficient Privileged LigandsCatalyst involved in:
• Oxidation of the δ-position via ruthenium catalysis1
• Stereoselective hydrogenation reactions of dehydroamino acid esters2 and macrocyclic peptideomimetics3
• Synthesis of cyclopeptide alkaloid mucronine E4, fluoro-containing amino acids5, and labeled protease inhibitors6

详细说明 (简体中文)

包装
50, 250 mg in glass bottle
Legal Information
与 Kanata Chemical Technologies Inc. 联合销售，仅供研究使用。这些化合物由 E.I. du Pont de Nemours and Company 授权制造和销售，此许可不包括利用这些化合物制备在制药领域销售的产品的权利。
Application
DuPhos and BPE Ligands: Highly Efficient Privileged LigandsCatalyst involved in:
• Oxidation of the δ-position via ruthenium catalysis1
• Stereoselective hydrogenation reactions of dehydroamino acid esters2 and macrocyclic peptideomimetics3
• Synthesis of cyclopeptide alkaloid mucronine E4, fluoro-containing amino acids5, and labeled protease inhibitors6